Whether or not there is economic value of comprehensive genomic profiling likely depends on what tissue type and what tumor type we’re talking about, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
Whether or not there is economic value of comprehensive genomic profiling likely depends on what tissue type and what tumor type we’re talking about, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
Transcript
In addition to being able to match certain patients with cancer to targeted therapies and clinical trials, is there a cost-benefit argument that can be made for covering comprehensive genomic profiling?
Comprehensive genomic profiling has been available for a number of years now. Priority Health was one of the first health plans in the country to cover next-generation sequencing, but we covered it in very limited circumstances. In patients where there was limited tissue, especially in non-small cell lung cancer, it made more economic sense to do next-generation sequencing rather than individual tumor analyses. We covered it in patients who had poor prognosis cancers in which it was important to understand what optimal therapy was the first time around in patients who had unsuccessfully completed prior therapy and were interested in clinical trials.
So, we covered it in very limited circumstances because it was important to understand the molecular profile for making subsequent treatment decisions. I think the question of whether or not there is an economic value to testing is probably very dependent on what tissue type and what tumor type we’re talking about. We’ve published some information with Foundation Medicine about the utility of next-generation sequencing and how physicians are using that information. I think as time progresses and physicians become more experienced in using those test results, we’ll see greater utlitity.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More